

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8194392

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PORTOLA PHARMACEUTICALS, INC.	09/17/2019
RECEIVING PARTY DATA	
Name:	SRX CARDIO, LLC
Street Address:	732 PITTSFORD-VICTOR ROAD
City:	PITTSFORD
State/Country:	NEW YORK
Postal Code:	14534
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17217848
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508152600
Email:	sdieu@sheppardmullin.com
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON LLP
Address Line 1:	650 TOWN CENTER DRIVE, 10TH FLOOR
Address Line 4:	COSTA MESA, CALIFORNIA 92626-1993
ATTORNEY DOCKET NUMBER:	69TJ-267796-US3
NAME OF SUBMITTER:	YOUNG CHANG
SIGNATURE:	/Young Chang/
DATE SIGNED:	09/28/2023
Total Attachments: 4	
source=Executed PCT Assignment Portola to SRX_69TJ-267796-US3#page1.tif	
source=Executed PCT Assignment Portola to SRX_69TJ-267796-US3#page2.tif	
source=Executed PCT Assignment Portola to SRX_69TJ-267796-US3#page3.tif	
source=Executed PCT Assignment Portola to SRX_69TJ-267796-US3#page4.tif	

ASSIGNMENT-WORLDWIDE
(Patent Application)

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Portola Pharmaceuticals, Inc.** (hereinafter referred to as "Assignor"), a corporation having a principal place of business at 270 E. Grand Avenue, South San Francisco, CA 94080 is an owner by way of assignment from named inventors, of the right, title and interest in and to the following patent applications (together with any patents that may issue therefrom and applications and patents that claim priority thereto, the "Patents"):

Atty. Dkt No.	Country	Appl. No.	Filing Date	Title
SRX000310US	US	62/298,852	2/23/2016	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein Activity
SRX000310EP	EP	16839890.7	8/19/2016	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
SRX000310HK	HK	18116351.9	8/19/2016	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
SRX000310PC	WO	PCT/US2016/047810	8/19/2016	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
SRX000310US	US	15/753,768	2/20/2018	Composition and Methods of Use of Novel Phenylalanine Small Organic Compounds to Directly Modulate PCSK9 Protein Activity
SRX000510EP	EP	16839887.3	8/19/2016	Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity
SRX000510HK	HK	16839887.3	8/19/2016	Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity
SRX000510PC	WO	PCT/US2016/047798	08/19/2016	Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity
SRX000510US	US	15/753,725	2/20/2018	Composition and Methods of Use of Tetrahydroisoquinoline Small Molecules to Bind and Modulate PCSK9 Protein Activity


SRX000601US	US	62/298,890	2/23/2016	Composition and Methods of Use of Phenylpiperazine Compounds that Bind and Modulate Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Activity
SRX000610EP	EP	16839893.1	8/19/2016	Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use
SRX000610HK	HK	18116354.6	8/19/2016	Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use
SRX000610PC	WO	PCT/US2016/047816	08/19/2016	Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators and Their Use
SRX000610US	US	15/753,790	2/20/2018	Phenylpiperazine Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Modulators And Their Use
PTL010700US	US	62/298,920	2/23/2016	Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9
PTL010710PC	WO	PCT/US2017/019189	2/23/2017	Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
PTL010710US	US	16/078,578	8/21/2018	Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
PTL011200US	US	62/465,493	03/01/2017	Compounds for Binding Proprotein Convertase Subtilisin/Kexin Type 9
PTL012100US	US	62/861,902	6/14/2019	Compounds for the Modulation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

1. Assignor agrees to assign, transfer, convey, and sell, and hereby assigns, transfers, conveys, and sells to **SRX Cardio, LLC**, having a principal place of business at 732 Pittsford-Victor Road, Pittsford, NY 14534, ("Assignee"), the entire right, title, and interest in and to the Patents, including:
- (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the Patents, implicitly or explicitly;
 - (b) the right to claim priority to the Patents, all applications based in whole or in part upon the Patent, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the Patents;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts,


continuations, continuations-in-part, divisional, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any Patent or that disclose or claim intellectual property in a Patent, in whole or in part;

- (d) the exclusive right to exclude other persons from practicing under the Patents (including provisional rights to reasonable royalties pursuant to 35 U.S.C. § 154(d)) and all claims for damages by reason of past infringement of any Patent, the right to sue for and collect such damages and royalties and/or seek equitable or other relief (including a preliminary or permanent injunction or other exclusionary order of any type) for past, current and future infringement of any Patent; and
 - (e) the exclusive rights to make, use, offer for sale, sell or import products and services that infringe under any Patent and to practice each of the same,
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the Patents.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such Patents or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside our signature.

Signature:  _____ Date: 9/17/19
Portola Pharmaceuticals, Inc.
Name: Mardi C. Dier
Title: Executive Vice President, Chief Financial Officer and Chief Business Officer

Assignment received and accepted by Assignee:

Signature:  _____ Date: September 12, 2019_____
SRX Cardio, LLC
Name: Kyle D. Monroe
Title: CFO